The VDH and Scott are advocating for people to get their vaccinations before winter. Scott said he has received his COVID ...

Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day. The average of price targets set by Wall Street analysts indicates a potential upside of 81.6 ...

"We believe that a bivalent booster vaccine, if authorised, would create a new tool as we continue to respond to emerging variants," added Bancel. The phase 1/2 study involved 895 subjects who ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day. The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial by next month and potential ...

The COVAIL trial reveals that neutralizing antibody titers correlate with COVID-19 risk reduction after mRNA boosters. Learn how this impacts vaccine strategies against emerging variants.

Inovio Pharmaceuticals Inc.-4.78% $75.45M ...

After hours: 7:59:53 p.m. EST ...